Stay updated on Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.

Latest updates to the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe Record History shows a new revision entry (v3.3.4) and removes the prior revision (v3.3.3). This is a log-level update to the history and does not modify the study data.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA new revision entry Revision: v3.3.3 was added to the history. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed from the footer.SummaryDifference0.2%

- Check52 days agoChange DetectedThe page history shows an added revision (v3.3.2) and a removed revision (v3.2.0); this reflects a UI/system update with no substantive changes to the study record.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoved a government funding/operating status notice from the page, a minor administrative update that does not affect study information or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check73 days agoChange DetectedThe new screenshot adds an extra version entry to the record history and shows minor UI tweaks; the primary study information and history structure remain unchanged.SummaryDifference0.2%

- Check102 days agoChange DetectedSummary of changes: added a government-operating-status notice and new v3.2.0 version tag; removed the old v3.1.0 tag. The page now communicates current funding-related limitations and where to check status, marking a conduction of a software/website update.SummaryDifference11%

Stay in the know with updates to Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.